Ligand Pharmaceuticals Incorporated (LGND)

73,54 +0,71 (+0,97%) Ab 03:13PM EDT. Markt geöffnet.

Ligand Pharmaceuticals Incorporated

555 Heritage Drive
Suite 200
Jupiter, FL 33458
United States
858 550 7500
https://www.ligand.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 58

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Matthew E. Korenberg	President & COO	831,77k	N/A	1975
Mr. Octavio Espinoza	Chief Financial Officer	613,59k	N/A	1971
Mr. Andrew T. Reardon J.D.	Chief Legal Officer & Secretary	614,87k	N/A	1975
Mr. Scott M. Plesha	Chief Executive Officer	N/A	N/A	1965
Mr. Paul J. Hadden	Senior Vice President of Investments & Business Development	N/A	N/A	N/A
Simon Latimer	Head of Investor Relations	N/A	N/A	N/A
Mr. Todd Pettingill	Director of Corporate Development	N/A	N/A	N/A
Ms. Audrey Warfield-Graham	Chief People Officer	N/A	N/A	N/A
Dr. Keith Marschke	Senior Vice President of Biology & Scientific Affairs	N/A	N/A	N/A
Dr. Vincent D. Antle	Senior Vice President of Technical Operations & QA - Capitsol	N/A	N/A	1969

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Corporate Governance

Ligand Pharmaceuticals Incorporateds ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 8, Vorstand: 5, Shareholderrechte: 5, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.